Hovione to create new campus and 100 jobs at New Jersey site
The new 31,000-sq. ft building will bring additional commercial spray drying capacity for customers who favour US-based manufacturing
Spray drying and particle engineering specialist Hovione has announced it is expanding its facilities at its East Windsor, New Jersey site with the creation of a state-of-the-art Hovione Campus.
The new 31,000-sq. ft (2900m2) building will be next to the company's existing site in New Jersey, laying the foundations of a Hovione Campus, and will bring additional commercial spray drying capacity online by 2023.
It will also allow the company to respond to customers favouring US-based manufacturing, from development all the way to commercial.
According to Hovione, the increased capacity will solidify its integrated offer ― API, particle engineering, drug product ― in the region.
The expansion, which was announced during CPHI Worldwide, in Milan, by Guy Villax, CEO, and Jean-Luc Herbeaux, COO, forms part of the company's $170 million global expansion strategy to increase capacity at its sites in the US, Ireland and Portugal leading to a global capacity increase of approximately 25%. The increased capacity will also create up to 100 jobs during the course of the next few years.
Filipe Tomás, General Manager at Hovione in New Jersey described the US market as "fundamental for the company" and this investment as "a key step in our expansion strategy".
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.